Please assess the completion status of the following clinical trial:

Trial Title: Genetics of QT Response to Moxifloxacin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Genotype in the highest and lowest quintiles of genetic predictors of QT interval duration~* Able to swallow pills~Exclusion Criteria:~* Inability to provide informed consent~* Prior known cardiovascular, renal, hepatic disease~* Personal or family history of sudden cardiac death~* Current use of prescribed or over-the-counter medications as well as recreational drugs~* Resting bradycardia (defined as resting heart rate \< 50 bpm)~* Conduction disease (QRS \> 100ms)~* QTc prolongation on electrocardiography (QTc \> 500msec)~* Abnormal potassium or magnesium serum level~* Abnormal renal or liver function tests~* Women who are nursing, pregnant or planning to become pregnant during the study period~* Tendon disorder or rupture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Moxifloxacin group (Type: EXPERIMENTAL): Healthy volunteers with QT genotype score in the highest or lowest quintile
- Placebo group (Type: PLACEBO_COMPARATOR): Healthy volunteers with QT genotype score in the highest or lowest quintile

Based on this trial design, predict the completion outcome and termination type (if applicable).